A5027441397- Neurological Disorders and Treatments
- Neurological Disease Mechanisms and Treatments
- Alzheimer's disease research and treatments
- Cholinesterase and Neurodegenerative Diseases
- Tryptophan and brain disorders
- Neuroinflammation and Neurodegeneration Mechanisms
- Mast cells and histamine
- Olfactory and Sensory Function Studies
- Migraine and Headache Studies
- Receptor Mechanisms and Signaling
- Amino Acid Enzymes and Metabolism
- Cerebrovascular and Carotid Artery Diseases
- Diet and metabolism studies
- Circadian rhythm and melatonin
- Neuroscience and Neuropharmacology Research
- Biochemical effects in animals
- Click Chemistry and Applications
- Neuropeptides and Animal Physiology
- Nicotinic Acetylcholine Receptors Study
- Pharmacological Effects of Medicinal Plants
- Dementia and Cognitive Impairment Research
- Biochemical Acid Research Studies
- Neurotransmitter Receptor Influence on Behavior
- Medicinal Plants and Bioactive Compounds
- Neuroendocrine regulation and behavior
Universidade da Coruña
2021
FC Barcelona
2018
Complejo Hospitalario Universitario de Santiago
2016
Iuliu Hațieganu University of Medicine and Pharmacy
2016
Complexo Hospitalario Universitario A Coruña
2016
University of California, San Diego
2016
Universidad de Granada
2016
EVER Neuro Pharma (Austria)
2016
EuroEspes Biomedical Research Center
2000-2011
Fundación Botín
2005
Cytidine 5'-diphosphocholine (citicoline) is a an endogenous intermediate in the biosynthesis of structural membrane phospholipids and brain acetylcholine. Citicoline has been extensively used for treatment neurodegenerative disorders associated with head trauma, stroke, aging, cerebrovascular pathology Alzheimer's disease. In this study we have investigated efficacy safety citicoline versus placebo patients Alzheimer Thirty (age = 73.0 +/- 8.5 years; range 57-87 years) mild to moderate...
Cerebrolysin (Cere) is a compound with neurotrophic activity shown to be effective in Alzheimer's disease earlier trials. The efficacy and safety of three dosages Cere were investigated this randomized, double‐blind, placebo‐controlled, study. Two hundred seventy‐nine patients enrolled (69 10 ml; 70 30 71 60 ml 69 placebo). Patients received iv infusions 10, 30, or placebo 5 days/week for the first 4 weeks thereafter, two per week 8 weeks. Effects on cognition clinical global impressions...
Background: Cerebrolysin is a neuropeptide preparation mimicking the effects of neurotrophic factors. This subgroup analysis assessed safety and efficacy in patients with moderate to moderately severe Alzheimer’s disease (AD) (ITT data set: N = 133; MMSE: 14–20) included dose‐finding study 251; 14–25). Results mild AD 118; 21–25) are also presented. Methods: Patients received 100 ml IV infusions (10, 30 or 60 diluted saline; 32, 34 35, respectively) placebo (saline; 32) over twelve weeks (5...
Treatment with neurotrophic agents might enhance and/or prolong the effects of cholinesterase inhibitors (ChEIs) in Alzheimers disease (AD). We compared safety and efficacy compound Cerebrolysin (10 ml; n=64), donepezil mg; n=66) a combination both treatments (n=67) mild-to-moderate (mini-mental state examination-MMSE score 12-25) probable AD patients enrolled randomized, double-blind trial. Primary endpoints were global outcome (Clinicians Interview-Based Impression Change plus caregiver...
Low circulating brain derived neurotrophic factor may promote cognitive deterioration, but the effects of and combination drug therapies on serum were not previously investigated in Alzheimer's disease. We evaluated Cerebrolysin, donepezil, combined therapy levels at week 16 (end Cerebrolysin treatment) 28 (endpoint) mild-to-moderate disease patients. increased 16, while enhanced it both study endpoint. Brain responses significantly higher group than donepezil groups 28, respectively....
Citicoline is an endogenous intermediate involved in the biosynthesis of brain phospholipids and acetylcholine which has been extensively used for treatment several neurodegenerative conditions. The effects citicoline on neurodegeneration, apoptosis learning were investigated male Sprague Dawley rats subjected to implants beta-amyloid fragment 1-40 (A beta 4: 3 Mmol) into right hippocampus permanent unilateral occlusion carotid artery. (CDP; 0, 62.5, 125 250 mg/kg/day i.p.) was given during...
CDP‐choline was given to patients with Alzheimer's disease (AD) at a daily dose of 1000 mg/day p.o. for one month. This compound slightly improved mental performance, tended reduce theta activity in fronto‐temporal regions, increasing alpha power occipital areas, and enhanced cerebrovascular perfusion by blood flow velocity reducing pulsatility resistance indexes. In addition, diminished histamine interleukin‐l levels serum, respectively, increased plasma TNF.
Cerebrolysin is a neuropeptide preparation mimicking the action of endogenous neurotrophic factors. Positive effects on β-amyloid- and tau-related pathologies, neuroinflammation, factors, oxidative stress, excitotoxicity, neurotransmission, brain metabolism, neuroplasticity, neuronal apoptosis degeneration, neurogenesis cognition were demonstrated in experimental conditions. These pleiotropic Alzheimer's disease-related pathogenic events are consistent with neurotrophic-like mode action,...
Vascular endothelial growth factor (VEGF) is an angioneurin involved in the regulation of vascular and neural functions relevant for pathophysiology Alzheimer’s disease (AD), but influence AD severity ApoE4 status on circulating VEGF its relationship with cognition has not bee n investigated. We assessed serum levels cognitive performance AD, amnestic mild impairment (MCI), control subjects. were higher patients than MCI cases controls (p < 0.05) showed a progressive increase clinical whole...
Rhytides represent an aesthetic problem for a large percentage of the population. Many methods, both noninvasive and invasive, have been used treatment wrinkles. Recently, long-pulsed 1064-nm Nd:YAG laser has shown to enhance dermal collagen synthesis without damaging epidermis. The purpose this preliminary study is evaluate use in nonablative periocular perioral Ten patients with facial wrinkles were treated laser, at spot size 5 mm diameter, energy density 13 J/cm2, exposure time per pulse...
Plasma neuronal-derived extracellular vesicles (NDEV) contain proteins of pathological, diagnostic, and therapeutic relevance.
The cholinergic dysfunction present in Alzheimer's disease (AD) might be due to a specific vulnerability of neurons linked neurotrophic imbalance, neuroimmune impairment, and/or direct effects β‐amyloid deposition and NFT formation ACh neurons. presence abnormal epitopes exposed on neuronal membranes may contribute the activation resting microglia initiating cascade leading cell destruction. According this hypothesis, multifactorial treatment AD should produce: 1) inhibition formation; 2)...
According to current scientific knowledge, excess tumour necrosis factor-α (TNF-α) and low insulin-like growth factor-I (IGF-I) are pathogenic-risk factors that constitute therapeutic targets for Alzheimer's disease (AD). Changes in serum TNF-α, total dissociable IGF-I levels were determined by ELISA 207 AD patients completing a 24-wk, double-blind, placebo-controlled trial evaluate the effects of neurotrophic compound Cerebrolysin (Cere: 10, 30 or 60 ml 12 wk). At week 24, Cere reduced...
Abstract Neurodegenerative disorders such as Alzheimer's disease (AD) are characterized by the loss of neurotrophic factors, and experimental therapeutical approaches to AD have investigated efficacy replacing or augmenting factor activity. Cerebrolysin, a peptide mixture with neurotrophic‐like effects, has been shown improve cognition in patients reduce synaptic behavioral deficits transgenic (tg) mice overexpressing amyloid precursor protein (APP). However, it is unclear how long‐lasting...
Traumatic brain injury (TBI) is a devastating medical condition that has an enormous socioeconomic impact because it affects more than 10 million people annually worldwide and associated with high rates of hospitalization, mortality disability. Although TBI survival improved continuously for decades, particularly in developing countries, implementation effective drug therapy represents unmet clinical need. All confirmatory trials conducted to date drugs targeting single pathological pathway...